董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hadar Ron | 女 | Director | 67 | 未披露 | 5.73 | 2026-02-10 |
| Moshe Mizrahy | 男 | Chief Executive Officer and Director | 73 | 21.60万美元 | 349.92 | 2026-02-10 |
| Michael Kreindel | 男 | Chief Technology Officer and Director | 59 | 26.70万美元 | 311.48 | 2026-02-10 |
| Nadav Kenneth | 男 | Director | 66 | 未披露 | 0.15 | 2026-02-10 |
| Michael Anghel | 男 | Chairman of the Board | 87 | 未披露 | 2.00 | 2026-02-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Moshe Mizrahy | 男 | Chief Executive Officer and Director | 73 | 21.60万美元 | 349.92 | 2026-02-10 |
| Yair Malca | 男 | Chief Financial Officer | 48 | 154.40万美元 | 13.71 | 2026-02-10 |
| Michael Kreindel | 男 | Chief Technology Officer and Director | 59 | 26.70万美元 | 311.48 | 2026-02-10 |
| Michael Dennison | 男 | President, North America | 45 | 199.90万美元 | 1.05 | 2026-02-10 |
董事简历
中英对照 | 中文 | 英文- Hadar Ron
-
Hadar Ron于2019年8月成为InMode Ltd.公司董事。自2000年以来，Ron博士一直是以色列生命科学风险投资基金Israel Healthcare Ventures的创始和管理合伙人。Ron博士还是以色列生命科学风险投资基金Israel Healthcare Ventures 2 LPIncorporated（IHCV2）管理公司的首席执行官。Ron博士担任专门从事结肠直肠筛查的医疗器械公司G.I. View Ltd.和信息技术初创公司CyTwist Ltd.的董事长，并担任以下公司的董事会成员：Home Skinovations Ltd.、SipNose Ltd.、Pet Novations Ltd.、Peri-Ness Technologies Ltd.、Viroblock Ltd.、O.G.D.H. Ltd.、OrSense Ltd.和NanoPass Technologies Ltd.。此外，Ron博士担任Together Pharma Ltd.的外部董事。此外，Ron博士还担任Momentum Fund的艾瑞博德成员，Momentum Fund是特拉维夫大学技术转让研究中心的成员，也是Birad Ltd的董事会成员，Bar Ilan大学的技术转让公司，也是以色列社会金融协会预防糖尿病和结肠癌的社会影响债券科学顾问委员会的主席。Ron医生是一名医生和受过教育的律师。她拥有特拉维夫大学的医学博士和法学博士学位，并曾在特拉维夫大学工商管理学院学习。
Hadar Ron became a director of the Company in Augt 2019. Since 2000, Dr. Ron has been the founding and managing partner of Israel Healthcare Ventures, an Israeli life science venture capital fund. Dr. Ron is also the chief executive officer of the management company for Israel Healthcare Ventures 2 LP Incorporated, or IHCV2, an Israeli life sciences venture capital fund. Dr. Ron serves as chairperson of G.I. View Ltd., a medical device company specializing in colorectal screenings, and Neurohelp Ltd., a Neurotechnology start up company, and as a board member of the following companies: Home Skinovations Ltd. (under voluntary liquidation), SipNose Ltd. (under voluntary liquidation), Pet Novations Ltd., Peri Ness Technologies Ltd., O.G.D.H. Ltd., OrSense Ltd., and Unbox Ventures Ltd. In addition, Dr. Ron serves as an external director of Together Pharma Ltd. In addition, Dr. Ron serves as a member of the advisory board of the Momentum Fund Tech Transfer of Tel Aviv University, a board member of BIRAD Ltd., the tech transfer company of Bar Ilan University, and is the chairperson of the scientific advisory board of Social Finance Israel's Social Impact Bond for the prevention of diabetes and colon cancer. Dr. Ron is a physician and attorney by education. She holds M.D. and L.L.B. degrees from Tel Aviv University and has studied at the School of Biness Administration at Tel Aviv University. - Hadar Ron于2019年8月成为InMode Ltd.公司董事。自2000年以来，Ron博士一直是以色列生命科学风险投资基金Israel Healthcare Ventures的创始和管理合伙人。Ron博士还是以色列生命科学风险投资基金Israel Healthcare Ventures 2 LPIncorporated（IHCV2）管理公司的首席执行官。Ron博士担任专门从事结肠直肠筛查的医疗器械公司G.I. View Ltd.和信息技术初创公司CyTwist Ltd.的董事长，并担任以下公司的董事会成员：Home Skinovations Ltd.、SipNose Ltd.、Pet Novations Ltd.、Peri-Ness Technologies Ltd.、Viroblock Ltd.、O.G.D.H. Ltd.、OrSense Ltd.和NanoPass Technologies Ltd.。此外，Ron博士担任Together Pharma Ltd.的外部董事。此外，Ron博士还担任Momentum Fund的艾瑞博德成员，Momentum Fund是特拉维夫大学技术转让研究中心的成员，也是Birad Ltd的董事会成员，Bar Ilan大学的技术转让公司，也是以色列社会金融协会预防糖尿病和结肠癌的社会影响债券科学顾问委员会的主席。Ron医生是一名医生和受过教育的律师。她拥有特拉维夫大学的医学博士和法学博士学位，并曾在特拉维夫大学工商管理学院学习。
- Hadar Ron became a director of the Company in Augt 2019. Since 2000, Dr. Ron has been the founding and managing partner of Israel Healthcare Ventures, an Israeli life science venture capital fund. Dr. Ron is also the chief executive officer of the management company for Israel Healthcare Ventures 2 LP Incorporated, or IHCV2, an Israeli life sciences venture capital fund. Dr. Ron serves as chairperson of G.I. View Ltd., a medical device company specializing in colorectal screenings, and Neurohelp Ltd., a Neurotechnology start up company, and as a board member of the following companies: Home Skinovations Ltd. (under voluntary liquidation), SipNose Ltd. (under voluntary liquidation), Pet Novations Ltd., Peri Ness Technologies Ltd., O.G.D.H. Ltd., OrSense Ltd., and Unbox Ventures Ltd. In addition, Dr. Ron serves as an external director of Together Pharma Ltd. In addition, Dr. Ron serves as a member of the advisory board of the Momentum Fund Tech Transfer of Tel Aviv University, a board member of BIRAD Ltd., the tech transfer company of Bar Ilan University, and is the chairperson of the scientific advisory board of Social Finance Israel's Social Impact Bond for the prevention of diabetes and colon cancer. Dr. Ron is a physician and attorney by education. She holds M.D. and L.L.B. degrees from Tel Aviv University and has studied at the School of Biness Administration at Tel Aviv University.
- Moshe Mizrahy
-
Moshe Mizrahy于2008年共同创立了该公司，自成立以来一直担任我们的首席执行官兼董事会主席。在此之前，Mizrahy先生是Syneron MedicalLtd.公司（一家位于以色列的医疗美容设备公司）的联合创始人兼首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，该公司是一家活跃于家庭使用市场的国际医疗美容消费设备公司，目前自2007年起担任其董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前担任以下公司的董事会成员:Sipnose Ltd.、Pet Novations Ltd.、Peri-ness Technologies Ltd.、Easy-Lap Ltd、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、New Forest Wood Products-2012Ltd.，M.N.Business Strategy Ltd.、Himalaya Family Office Advisory Ltd.和Polimer Logistics Israel Ltd.Mizrahy先生在特拉维夫大学（Tel Aviv University）获得工程学学士学位，并在纽约佩斯大学（Pace University）获得工商管理硕士学位。
Moshe Mizrahy co founded the Company in 2008 and has been Chief Executive Officer and Director since inception and served as the Chairman of board of directors from 2008 to July 2024. Prior to that, Mr. Mizrahy was co founder and chief executive officer of Syneron Medical Ltd., a medical aesthetic device company based in Israel. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd. (under voluntary liquidation), an international medical aesthetic consumer devices company that was active in the home e market. In addition, Mr. Mizrahy currently sits on the board of directors of the following companies: Alto Real Estate Management (IL) Ltd., Aquapass Ltd., G.I. View Ltd., Himalaya (P.T.C) M.M 2021 Ltd., SipNose Ltd. (under voluntary liquidation), Pet Novations Ltd., Peri Ness Technologies Ltd., Urifer Ltd., Escape Rescue Systems Ltd. (under voluntary liquidation), New Forest Wood Products (2012) Ltd., Med Smart Hub Ltd., Ivy Next Ltd., MM INMD Ltd., Mizliz Real Estate Ltd., M.N. Biness Strategy Ltd., Nidaria Technology Ltd., and Himalaya Family Office Advising Ltd. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York. - Moshe Mizrahy于2008年共同创立了该公司，自成立以来一直担任我们的首席执行官兼董事会主席。在此之前，Mizrahy先生是Syneron MedicalLtd.公司（一家位于以色列的医疗美容设备公司）的联合创始人兼首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，该公司是一家活跃于家庭使用市场的国际医疗美容消费设备公司，目前自2007年起担任其董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前担任以下公司的董事会成员:Sipnose Ltd.、Pet Novations Ltd.、Peri-ness Technologies Ltd.、Easy-Lap Ltd、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、New Forest Wood Products-2012Ltd.，M.N.Business Strategy Ltd.、Himalaya Family Office Advisory Ltd.和Polimer Logistics Israel Ltd.Mizrahy先生在特拉维夫大学（Tel Aviv University）获得工程学学士学位，并在纽约佩斯大学（Pace University）获得工商管理硕士学位。
- Moshe Mizrahy co founded the Company in 2008 and has been Chief Executive Officer and Director since inception and served as the Chairman of board of directors from 2008 to July 2024. Prior to that, Mr. Mizrahy was co founder and chief executive officer of Syneron Medical Ltd., a medical aesthetic device company based in Israel. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd. (under voluntary liquidation), an international medical aesthetic consumer devices company that was active in the home e market. In addition, Mr. Mizrahy currently sits on the board of directors of the following companies: Alto Real Estate Management (IL) Ltd., Aquapass Ltd., G.I. View Ltd., Himalaya (P.T.C) M.M 2021 Ltd., SipNose Ltd. (under voluntary liquidation), Pet Novations Ltd., Peri Ness Technologies Ltd., Urifer Ltd., Escape Rescue Systems Ltd. (under voluntary liquidation), New Forest Wood Products (2012) Ltd., Med Smart Hub Ltd., Ivy Next Ltd., MM INMD Ltd., Mizliz Real Estate Ltd., M.N. Biness Strategy Ltd., Nidaria Technology Ltd., and Himalaya Family Office Advising Ltd. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York.
- Michael Kreindel
-
Michael Kreindel于2008年共同创立了该公司，并自成立以来一直担任我们的首席技术官。Kreindel博士于2019年8月成为公司董事。他曾于2001年至2007年担任Syneron MedicalLtd.的联合创始人和首席技术官。Kreindel博士拥有物理学和数学博士学位，也毕业于俄罗斯乌拉尔理工大学（Ural Politechnical Institute），担任实验和理论核物理的工程师和物理学家。
Michael Kreindel co founded the Company in 2008 and has served as Chief Technology Officer since inception. Dr. Kreindel became a director for the Company in Augt 2019. He previoly was a co founder of, and served as CTO of, Syneron Medical Ltd. from 2001 to 2007. Dr. Kreindel has a Ph.D. in physics and mathematics, and also graduated as an engineer and physicist in experimental and theoretical nuclear physics from Ural Politechnical Institute, Rsia. - Michael Kreindel于2008年共同创立了该公司，并自成立以来一直担任我们的首席技术官。Kreindel博士于2019年8月成为公司董事。他曾于2001年至2007年担任Syneron MedicalLtd.的联合创始人和首席技术官。Kreindel博士拥有物理学和数学博士学位，也毕业于俄罗斯乌拉尔理工大学（Ural Politechnical Institute），担任实验和理论核物理的工程师和物理学家。
- Michael Kreindel co founded the Company in 2008 and has served as Chief Technology Officer since inception. Dr. Kreindel became a director for the Company in Augt 2019. He previoly was a co founder of, and served as CTO of, Syneron Medical Ltd. from 2001 to 2007. Dr. Kreindel has a Ph.D. in physics and mathematics, and also graduated as an engineer and physicist in experimental and theoretical nuclear physics from Ural Politechnical Institute, Rsia.
- Nadav Kenneth
-
Nadav Kenneth于2024年4月成为公司董事。Kenneth先生在以色列陆军情报部队（8200部队）服务了22年，在那里他领导了大型研发职能，负责战略规划部门（计划、方法、预算编制和监测），并指挥了一个情报部门。任职后，肯尼斯共同创立、管理并担任多家初创公司的董事会成员，曾任职于一家大型蜂窝运营商，并为公司和官方实体提供咨询服务。2009年，Kenneth co先生创立了QRative Ltd.，该公司开发了一个基于人工智能的知识产权分析和结晶平台，并在2009年至2022年期间担任其首席执行官和董事会成员。2007年至2011年，Kenneth先生就桑给巴尔税务局的重组以及建立政府的人力资源和工资制度向桑给巴尔政府提供了咨询。2004年，Kenneth co先生创立了Trisixty Security，该公司开发了一种自动化系统，可监控IT安全法规的遵守情况，并在2004年至2006年期间担任其国家经理和董事会成员。从2014年到2020年，Kenneth先生担任了一家职前教育非政府组织（Mechinat Aderet）的志愿者主席。Kenneth先生拥有Bar Ilan大学的经济学和政治学学士学位，以及亚特兰大/以色列斯威本大学的Biness Entrepreneurship硕士学位。
Nadav Kenneth became a director of the Company in April 2024.Mr. Kenneth served for 22 years in the Israeli Army's Intelligence corps (Unit 8200) where he led large R&D functions, was in charge of the strategic planning branch (plans, methodology, budgeting and monitoring) and commanded an intelligence unit. Following his service, Mr. Kenneth co founded, managed and served as a board member of several startup companies, worked for a large cellular operator, and provided consultation to companies and official entities. In 2009, Mr. Kenneth co founded Qrative Ltd., which developed an AI based platform for analysis and crystallization of intellectual property and served as its CEO and board member from 2009 to 2022. From 2007 to 2011, Mr. Kenneth provided consultation to the Government of Zanzibar with respect to restructuring of the Zanzibar Revenue Authority and setting up the government's HR and payroll systems. In 2004, Mr. Kenneth co founded Trisixty Security, which developed an automated system that monitored compliance with IT security regulations, and served as its country manager and board member from 2004 to 2006. From 2014 to 2020, Mr. Kenneth served as volunteer Chairman of a pre service education NGO (Mechinat Aderet). Mr. Kenneth holds a B.A. in Economics and Political Sciences from the Bar Ilan University and an M.A. in Biness Entrepreneurship from the Swinburne University in Atralia/Israel. - Nadav Kenneth于2024年4月成为公司董事。Kenneth先生在以色列陆军情报部队（8200部队）服务了22年，在那里他领导了大型研发职能，负责战略规划部门（计划、方法、预算编制和监测），并指挥了一个情报部门。任职后，肯尼斯共同创立、管理并担任多家初创公司的董事会成员，曾任职于一家大型蜂窝运营商，并为公司和官方实体提供咨询服务。2009年，Kenneth co先生创立了QRative Ltd.，该公司开发了一个基于人工智能的知识产权分析和结晶平台，并在2009年至2022年期间担任其首席执行官和董事会成员。2007年至2011年，Kenneth先生就桑给巴尔税务局的重组以及建立政府的人力资源和工资制度向桑给巴尔政府提供了咨询。2004年，Kenneth co先生创立了Trisixty Security，该公司开发了一种自动化系统，可监控IT安全法规的遵守情况，并在2004年至2006年期间担任其国家经理和董事会成员。从2014年到2020年，Kenneth先生担任了一家职前教育非政府组织（Mechinat Aderet）的志愿者主席。Kenneth先生拥有Bar Ilan大学的经济学和政治学学士学位，以及亚特兰大/以色列斯威本大学的Biness Entrepreneurship硕士学位。
- Nadav Kenneth became a director of the Company in April 2024.Mr. Kenneth served for 22 years in the Israeli Army's Intelligence corps (Unit 8200) where he led large R&D functions, was in charge of the strategic planning branch (plans, methodology, budgeting and monitoring) and commanded an intelligence unit. Following his service, Mr. Kenneth co founded, managed and served as a board member of several startup companies, worked for a large cellular operator, and provided consultation to companies and official entities. In 2009, Mr. Kenneth co founded Qrative Ltd., which developed an AI based platform for analysis and crystallization of intellectual property and served as its CEO and board member from 2009 to 2022. From 2007 to 2011, Mr. Kenneth provided consultation to the Government of Zanzibar with respect to restructuring of the Zanzibar Revenue Authority and setting up the government's HR and payroll systems. In 2004, Mr. Kenneth co founded Trisixty Security, which developed an automated system that monitored compliance with IT security regulations, and served as its country manager and board member from 2004 to 2006. From 2014 to 2020, Mr. Kenneth served as volunteer Chairman of a pre service education NGO (Mechinat Aderet). Mr. Kenneth holds a B.A. in Economics and Political Sciences from the Bar Ilan University and an M.A. in Biness Entrepreneurship from the Swinburne University in Atralia/Israel.
- Michael Anghel
-
Michael Anghel于2019年8月成为公司董事。他自2010年起担任BiolineRx Ltd.（纳斯达克股票代码：BLRX）的董事会成员，自2010年起担任BiolineRx的投资监督委员会成员。从1977年到1999年，他领导贴现投资有限公司（IDB集团的）在技术和通信领域的活动。1999年，他创立了先进技术投资公司CAP Ventures。从2004年到2005年，他担任以色列贴现银行（TASE： DSCT）的投资银行部门DCM的首席执行官。他目前担任BiolineRx Ltd.（纳斯达克股票代码：BLRX）的董事会成员，以及Ellomay Capital Ltd.（纽约证券交易所股票代码：ELLO）的审计委员会主席和薪酬委员会主席。直到最近，他还担任the Center for Educational Technology的主席和Lahav Ltd （Tel-Aviv University Executive Program）的董事长。在开始他的商业生涯之前，他曾担任Tel Aviv大学工商管理研究生院的全职成员，在那里他教授金融和企业战略。他持有the Hebrew University（位于耶路撒冷）的经济学学士学位，以及Columbia University（位于纽约）的工商管理硕士学位和金融学博士学位。
Michael Anghel became the Chairman of the board of directors effective July 25, 2024. Dr. Anghel has been a director of the Company in Augt 2019. Dr. Anghel has previoly served on the board of directors and on the Investment Monitoring Committee of BiolineRx Ltd. (Nasdaq: BLRX) since 2010 and until 2024. From 1977 to 1999, he led the Discount Investment Corporation Ltd. (of the IDB Group) activities in the fields of technology and communications. In 1999, he founded CAP Ventures, an advanced technology investment company. From 2004 to 2005, Dr. Anghel served as CEO of DCM, the investment banking arm of the Israel Discount Bank (TASE: DSCT). Dr. Anghel has also previoly served as the Chairman of the Audit Committee and the Chairman of the Remuneration Committee of Ellomay Capital Ltd. (NYSE, TASE: ELLO) until December 2023. Mr. Anghel also previoly served as the chairman of the Center for Educational Technology and as the Chairman of the board of directors of Lahav Ltd (Tel Aviv University Executive Program). Prior to launching his biness career, Dr. Anghel served as a full time member of the Graduate School of Biness Administration of the Tel Aviv University, where he taught finance and corporate strategy. Dr. Anghel holds a B.A. in Economics from the Hebrew University in Jeralem and an M.B.A. and Ph.D. in Finance from Columbia University, New York. - Michael Anghel于2019年8月成为公司董事。他自2010年起担任BiolineRx Ltd.（纳斯达克股票代码：BLRX）的董事会成员，自2010年起担任BiolineRx的投资监督委员会成员。从1977年到1999年，他领导贴现投资有限公司（IDB集团的）在技术和通信领域的活动。1999年，他创立了先进技术投资公司CAP Ventures。从2004年到2005年，他担任以色列贴现银行（TASE： DSCT）的投资银行部门DCM的首席执行官。他目前担任BiolineRx Ltd.（纳斯达克股票代码：BLRX）的董事会成员，以及Ellomay Capital Ltd.（纽约证券交易所股票代码：ELLO）的审计委员会主席和薪酬委员会主席。直到最近，他还担任the Center for Educational Technology的主席和Lahav Ltd （Tel-Aviv University Executive Program）的董事长。在开始他的商业生涯之前，他曾担任Tel Aviv大学工商管理研究生院的全职成员，在那里他教授金融和企业战略。他持有the Hebrew University（位于耶路撒冷）的经济学学士学位，以及Columbia University（位于纽约）的工商管理硕士学位和金融学博士学位。
- Michael Anghel became the Chairman of the board of directors effective July 25, 2024. Dr. Anghel has been a director of the Company in Augt 2019. Dr. Anghel has previoly served on the board of directors and on the Investment Monitoring Committee of BiolineRx Ltd. (Nasdaq: BLRX) since 2010 and until 2024. From 1977 to 1999, he led the Discount Investment Corporation Ltd. (of the IDB Group) activities in the fields of technology and communications. In 1999, he founded CAP Ventures, an advanced technology investment company. From 2004 to 2005, Dr. Anghel served as CEO of DCM, the investment banking arm of the Israel Discount Bank (TASE: DSCT). Dr. Anghel has also previoly served as the Chairman of the Audit Committee and the Chairman of the Remuneration Committee of Ellomay Capital Ltd. (NYSE, TASE: ELLO) until December 2023. Mr. Anghel also previoly served as the chairman of the Center for Educational Technology and as the Chairman of the board of directors of Lahav Ltd (Tel Aviv University Executive Program). Prior to launching his biness career, Dr. Anghel served as a full time member of the Graduate School of Biness Administration of the Tel Aviv University, where he taught finance and corporate strategy. Dr. Anghel holds a B.A. in Economics from the Hebrew University in Jeralem and an M.B.A. and Ph.D. in Finance from Columbia University, New York.
高管简历
中英对照 | 中文 | 英文- Moshe Mizrahy
Moshe Mizrahy于2008年共同创立了该公司，自成立以来一直担任我们的首席执行官兼董事会主席。在此之前，Mizrahy先生是Syneron MedicalLtd.公司（一家位于以色列的医疗美容设备公司）的联合创始人兼首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，该公司是一家活跃于家庭使用市场的国际医疗美容消费设备公司，目前自2007年起担任其董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前担任以下公司的董事会成员:Sipnose Ltd.、Pet Novations Ltd.、Peri-ness Technologies Ltd.、Easy-Lap Ltd、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、New Forest Wood Products-2012Ltd.，M.N.Business Strategy Ltd.、Himalaya Family Office Advisory Ltd.和Polimer Logistics Israel Ltd.Mizrahy先生在特拉维夫大学（Tel Aviv University）获得工程学学士学位，并在纽约佩斯大学（Pace University）获得工商管理硕士学位。
Moshe Mizrahy co founded the Company in 2008 and has been Chief Executive Officer and Director since inception and served as the Chairman of board of directors from 2008 to July 2024. Prior to that, Mr. Mizrahy was co founder and chief executive officer of Syneron Medical Ltd., a medical aesthetic device company based in Israel. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd. (under voluntary liquidation), an international medical aesthetic consumer devices company that was active in the home e market. In addition, Mr. Mizrahy currently sits on the board of directors of the following companies: Alto Real Estate Management (IL) Ltd., Aquapass Ltd., G.I. View Ltd., Himalaya (P.T.C) M.M 2021 Ltd., SipNose Ltd. (under voluntary liquidation), Pet Novations Ltd., Peri Ness Technologies Ltd., Urifer Ltd., Escape Rescue Systems Ltd. (under voluntary liquidation), New Forest Wood Products (2012) Ltd., Med Smart Hub Ltd., Ivy Next Ltd., MM INMD Ltd., Mizliz Real Estate Ltd., M.N. Biness Strategy Ltd., Nidaria Technology Ltd., and Himalaya Family Office Advising Ltd. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York.- Moshe Mizrahy于2008年共同创立了该公司，自成立以来一直担任我们的首席执行官兼董事会主席。在此之前，Mizrahy先生是Syneron MedicalLtd.公司（一家位于以色列的医疗美容设备公司）的联合创始人兼首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，该公司是一家活跃于家庭使用市场的国际医疗美容消费设备公司，目前自2007年起担任其董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前担任以下公司的董事会成员:Sipnose Ltd.、Pet Novations Ltd.、Peri-ness Technologies Ltd.、Easy-Lap Ltd、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、New Forest Wood Products-2012Ltd.，M.N.Business Strategy Ltd.、Himalaya Family Office Advisory Ltd.和Polimer Logistics Israel Ltd.Mizrahy先生在特拉维夫大学（Tel Aviv University）获得工程学学士学位，并在纽约佩斯大学（Pace University）获得工商管理硕士学位。
- Moshe Mizrahy co founded the Company in 2008 and has been Chief Executive Officer and Director since inception and served as the Chairman of board of directors from 2008 to July 2024. Prior to that, Mr. Mizrahy was co founder and chief executive officer of Syneron Medical Ltd., a medical aesthetic device company based in Israel. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd. (under voluntary liquidation), an international medical aesthetic consumer devices company that was active in the home e market. In addition, Mr. Mizrahy currently sits on the board of directors of the following companies: Alto Real Estate Management (IL) Ltd., Aquapass Ltd., G.I. View Ltd., Himalaya (P.T.C) M.M 2021 Ltd., SipNose Ltd. (under voluntary liquidation), Pet Novations Ltd., Peri Ness Technologies Ltd., Urifer Ltd., Escape Rescue Systems Ltd. (under voluntary liquidation), New Forest Wood Products (2012) Ltd., Med Smart Hub Ltd., Ivy Next Ltd., MM INMD Ltd., Mizliz Real Estate Ltd., M.N. Biness Strategy Ltd., Nidaria Technology Ltd., and Himalaya Family Office Advising Ltd. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York.
- Yair Malca
Yair Malca自2017年以来一直担任我们的首席财务官。马尔卡先生曾于2013年至2017年担任集成电路和半导体开发商Jazz Semiconductor，Inc.的财务总监。此前，他曾担任Syneron公司的总会计师（从2008年到2013年）、EZchip Semiconductor公司（网络处理器供应商）的助理总会计师（从2007年到2008年）、Bermad公司（液压控制阀供应商）的子公司总会计师（从2007年到2008年）。从2005年到2007年并从2002年到2005年在Ernst&Young开始他的公共会计职业生涯。Malca先生拥有海法大学（Haifa University）的会计与经济学学士学位和特拉维夫大学（Tel Aviv University）的工商管理硕士学位，并且是以色列的注册会计师。
Yair Malca has served as Chief Financial Officer since 2017. In his previo role, Mr. Malca was the Director of Finance for Jazz Semiconductor, Inc., a developer of integrated circuits and semiconductors, from 2013 to 2017. Before that, he served as the controller of Syneron from 2008 to 2013, as assistant controller of EZchip Semiconductor, a provider of network processors, from 2007 to 2008, as subsidiary controller of Bermad, a provider of hydraulic control valves, from 2005 to 2007, and began his career in public accounting at Ernst & Young from 2002 to 2005. Mr. Malca holds a B.A. in Accounting and Economics from Haifa University and an MBA from Tel Aviv University, and is a Certified Public Accountant in Israel.- Yair Malca自2017年以来一直担任我们的首席财务官。马尔卡先生曾于2013年至2017年担任集成电路和半导体开发商Jazz Semiconductor，Inc.的财务总监。此前，他曾担任Syneron公司的总会计师（从2008年到2013年）、EZchip Semiconductor公司（网络处理器供应商）的助理总会计师（从2007年到2008年）、Bermad公司（液压控制阀供应商）的子公司总会计师（从2007年到2008年）。从2005年到2007年并从2002年到2005年在Ernst&Young开始他的公共会计职业生涯。Malca先生拥有海法大学（Haifa University）的会计与经济学学士学位和特拉维夫大学（Tel Aviv University）的工商管理硕士学位，并且是以色列的注册会计师。
- Yair Malca has served as Chief Financial Officer since 2017. In his previo role, Mr. Malca was the Director of Finance for Jazz Semiconductor, Inc., a developer of integrated circuits and semiconductors, from 2013 to 2017. Before that, he served as the controller of Syneron from 2008 to 2013, as assistant controller of EZchip Semiconductor, a provider of network processors, from 2007 to 2008, as subsidiary controller of Bermad, a provider of hydraulic control valves, from 2005 to 2007, and began his career in public accounting at Ernst & Young from 2002 to 2005. Mr. Malca holds a B.A. in Accounting and Economics from Haifa University and an MBA from Tel Aviv University, and is a Certified Public Accountant in Israel.
- Michael Kreindel
Michael Kreindel于2008年共同创立了该公司，并自成立以来一直担任我们的首席技术官。Kreindel博士于2019年8月成为公司董事。他曾于2001年至2007年担任Syneron MedicalLtd.的联合创始人和首席技术官。Kreindel博士拥有物理学和数学博士学位，也毕业于俄罗斯乌拉尔理工大学（Ural Politechnical Institute），担任实验和理论核物理的工程师和物理学家。
Michael Kreindel co founded the Company in 2008 and has served as Chief Technology Officer since inception. Dr. Kreindel became a director for the Company in Augt 2019. He previoly was a co founder of, and served as CTO of, Syneron Medical Ltd. from 2001 to 2007. Dr. Kreindel has a Ph.D. in physics and mathematics, and also graduated as an engineer and physicist in experimental and theoretical nuclear physics from Ural Politechnical Institute, Rsia.- Michael Kreindel于2008年共同创立了该公司，并自成立以来一直担任我们的首席技术官。Kreindel博士于2019年8月成为公司董事。他曾于2001年至2007年担任Syneron MedicalLtd.的联合创始人和首席技术官。Kreindel博士拥有物理学和数学博士学位，也毕业于俄罗斯乌拉尔理工大学（Ural Politechnical Institute），担任实验和理论核物理的工程师和物理学家。
- Michael Kreindel co founded the Company in 2008 and has served as Chief Technology Officer since inception. Dr. Kreindel became a director for the Company in Augt 2019. He previoly was a co founder of, and served as CTO of, Syneron Medical Ltd. from 2001 to 2007. Dr. Kreindel has a Ph.D. in physics and mathematics, and also graduated as an engineer and physicist in experimental and theoretical nuclear physics from Ural Politechnical Institute, Rsia.
- Michael Dennison
迈克尔·丹尼森自2025年9月起担任新任命的北美总裁。在担任之前的职务时，Dennison先生曾在公司担任多个职位，包括2018年至2022年的销售经理、2022年至2024年的区域经理以及2024年至2025年的副总裁。丹尼森先生拥有伊利湖拼贴画公司的Biness学位。
Michael Dennison serves as newly appointed President of North America since September 2025. In his previo roles, Mr. Dennison served in several positions in the Company, including as a sales manager from 2018 to 2022, regional manager from 2022 to 2024, and vice president from 2024 to 2025. Mr. Dennison holds a degree in Biness from Lake Erie Collage.- 迈克尔·丹尼森自2025年9月起担任新任命的北美总裁。在担任之前的职务时，Dennison先生曾在公司担任多个职位，包括2018年至2022年的销售经理、2022年至2024年的区域经理以及2024年至2025年的副总裁。丹尼森先生拥有伊利湖拼贴画公司的Biness学位。
- Michael Dennison serves as newly appointed President of North America since September 2025. In his previo roles, Mr. Dennison served in several positions in the Company, including as a sales manager from 2018 to 2022, regional manager from 2022 to 2024, and vice president from 2024 to 2025. Mr. Dennison holds a degree in Biness from Lake Erie Collage.